Laurent Dercle1, Dana E Connors1, Ying Tang1, Stacey J Adam1, Mithat Gönen1, Patrick Hilden1, Sanja Karovic1, Michael Maitland1, Chaya S Moskowitz1, Gary Kelloff1, Binsheng Zhao1, Geoffrey R Oxnard1, Lawrence H Schwartz1. 1. Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Abstract
PURPOSE: To develop a public-private partnership to study the feasibility of a new approach in collecting and analyzing clinically annotated imaging data from landmark phase III trials in advanced solid tumors. PATIENTS AND METHODS: The collection of clinical trials fulfilled the following inclusion criteria: completed randomized trials of > 300 patients, highly measurable solid tumors (non-small-cell lung cancer, colorectal cancer, renal cell cancer, and melanoma), and required sponsor and institutional review board sign-offs. The new approach in analyzing computed tomography scans was to transfer to an academic image analysis laboratory, draw contours semi-automatically by using in-house-developed algorithms integrated into the open source imaging platform Weasis, and perform serial volumetric measurement. RESULTS: The median duration of contracting with five sponsors was 12 months. Ten trials in 7,085 patients that covered 12 treatment regimens across 20 trial arms were collected. To date, four trials in 3,954 patients were analyzed. Source imaging data were transferred to the academic core from 97% of trial patients (n = 3,837). Tumor imaging measurements were extracted from 82% of transferred computed tomography scans (n = 3,162). Causes of extraction failure were nonmeasurable disease (n = 392), single imaging time point (n = 224), and secondary captured images (n = 59). Overall, clinically annotated imaging data were extracted in 79% of patients (n = 3,055), and the primary trial end point analysis in each trial remained representative of each original trial end point. CONCLUSION: The sharing and analysis of source imaging data from large randomized trials is feasible and offer a rich and reusable, but largely untapped, resource for future research on novel trial-level response and progression imaging metrics.
PURPOSE: To develop a public-private partnership to study the feasibility of a new approach in collecting and analyzing clinically annotated imaging data from landmark phase III trials in advanced solid tumors. PATIENTS AND METHODS: The collection of clinical trials fulfilled the following inclusion criteria: completed randomized trials of > 300 patients, highly measurable solid tumors (non-small-cell lung cancer, colorectal cancer, renal cell cancer, and melanoma), and required sponsor and institutional review board sign-offs. The new approach in analyzing computed tomography scans was to transfer to an academic image analysis laboratory, draw contours semi-automatically by using in-house-developed algorithms integrated into the open source imaging platform Weasis, and perform serial volumetric measurement. RESULTS: The median duration of contracting with five sponsors was 12 months. Ten trials in 7,085 patients that covered 12 treatment regimens across 20 trial arms were collected. To date, four trials in 3,954 patients were analyzed. Source imaging data were transferred to the academic core from 97% of trial patients (n = 3,837). Tumor imaging measurements were extracted from 82% of transferred computed tomography scans (n = 3,162). Causes of extraction failure were nonmeasurable disease (n = 392), single imaging time point (n = 224), and secondary captured images (n = 59). Overall, clinically annotated imaging data were extracted in 79% of patients (n = 3,055), and the primary trial end point analysis in each trial remained representative of each original trial end point. CONCLUSION: The sharing and analysis of source imaging data from large randomized trials is feasible and offer a rich and reusable, but largely untapped, resource for future research on novel trial-level response and progression imaging metrics.
Authors: Geoffrey R Oxnard; Binsheng Zhao; Camelia S Sima; Michelle S Ginsberg; Leonard P James; Robert A Lefkowitz; Pingzhen Guo; Mark G Kris; Lawrence H Schwartz; Gregory J Riely Journal: J Clin Oncol Date: 2011-07-05 Impact factor: 44.544
Authors: J Y Douillard; S Siena; J Cassidy; J Tabernero; R Burkes; M Barugel; Y Humblet; G Bodoky; D Cunningham; J Jassem; F Rivera; I Kocákova; P Ruff; M Błasińska-Morawiec; M Smakal; J L Canon; M Rother; K S Oliner; Y Tian; F Xu; R Sidhu Journal: Ann Oncol Date: 2014-04-08 Impact factor: 32.976
Authors: Robert J Motzer; Thomas E Hutson; David Cella; James Reeves; Robert Hawkins; Jun Guo; Paul Nathan; Michael Staehler; Paul de Souza; Jaime R Merchan; Ekaterini Boleti; Kate Fife; Jie Jin; Robert Jones; Hirotsugu Uemura; Ugo De Giorgi; Ulrika Harmenberg; Jinwan Wang; Cora N Sternberg; Keith Deen; Lauren McCann; Michelle D Hackshaw; Rocco Crescenzo; Lini N Pandite; Toni K Choueiri Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: Geoffrey R Oxnard; Michael J Morris; F Stephen Hodi; Laurence H Baker; Mark G Kris; Alan P Venook; Lawrence H Schwartz Journal: J Natl Cancer Inst Date: 2012-08-27 Impact factor: 13.506
Authors: Cora N Sternberg; Ian D Davis; Jozef Mardiak; Cezary Szczylik; Eunsik Lee; John Wagstaff; Carlos H Barrios; Pamela Salman; Oleg A Gladkov; Alexander Kavina; Juan J Zarbá; Mei Chen; Lauren McCann; Lini Pandite; Debasish F Roychowdhury; Robert E Hawkins Journal: J Clin Oncol Date: 2010-01-25 Impact factor: 44.544
Authors: C H Li; R R Bies; Y Wang; M R Sharma; S Karovic; L Werk; M J Edelman; A A Miller; E E Vokes; A Oto; M J Ratain; L H Schwartz; M L Maitland Journal: Clin Transl Sci Date: 2016-01-21 Impact factor: 4.689
Authors: Laurent Dercle; Lin Lu; Lawrence H Schwartz; Min Qian; Sabine Tejpar; Peter Eggleton; Binsheng Zhao; Hubert Piessevaux Journal: J Natl Cancer Inst Date: 2020-09-01 Impact factor: 13.506
Authors: Firas S Ahmed; Laurent Dercle; Gregory V Goldmacher; Hao Yang; Dana Connors; Ying Tang; Sanja Karovic; Binsheng Zhao; Richard D Carvajal; Caroline Robert; Michael L Maitland; Geoffrey R Oxnard; Lawrence H Schwartz Journal: Eur Radiol Date: 2020-09-30 Impact factor: 7.034
Authors: Michael L Maitland; Julia Wilkerson; Sanja Karovic; Binsheng Zhao; Jessica Flynn; Mengxi Zhou; Patrick Hilden; Firas S Ahmed; Laurent Dercle; Chaya S Moskowitz; Ying Tang; Dana E Connors; Stacey J Adam; Gary Kelloff; Mithat Gonen; Tito Fojo; Lawrence H Schwartz; Geoffrey R Oxnard Journal: Clin Cancer Res Date: 2020-09-28 Impact factor: 12.531